Coenzyme Q10 Doesn't Prevent Periprocedural Myocardial Injury

This article originally appeared here.
Share this content:
Coenzyme Q10 Doesn't Prevent Periprocedural Myocardial Injury
Coenzyme Q10 Doesn't Prevent Periprocedural Myocardial Injury

MONDAY, July 25, 2016 (HealthDay News) -- Pre-treatment with coenzyme Q10 (CoQ10) before elective percutaneous coronary intervention (PCI) does not reduce periprocedural myocardial injury (PMI), but does significantly decrease high-sensitivity C-reactive protein (hs-CRP) levels, according to a study published online July 6 in Cardiovascular Therapeutics.

Naser Aslanabadi, M.D., from the Tabriz University of Medical Sciences in Iran, and colleagues randomized 100 patients scheduled for elective PCI to receive a 300-mg loading dose CoQ10 12 hours before procedure. Creatine kinase-MB (CK-MB) and troponin-I levels were measured before procedure, and eight and 24 hours after, while hs-CRP was measured at baseline and 24 hours after.

The researchers observed no differences in CK-MB elevation (above the upper limit normal) between the two groups (P = 0.806). Similarly, elevated troponin-I was the same in both groups. There was no significant change seen in the level of cardiac biomarkers. However, a significant reduction in hs-CRP level occurred in the CoQ10 group (P = 0.032).

"The results showed that pretreatment with 300-mg CoQ10 12 hours before procedure could not [reduce] PMI following elective PCI; however, [it] significantly decreased hs-CRP, which can partially support the anti-inflammatory effects of CoQ10 in preventing PMI," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »